



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 24 2003

TECH CENTER 1600/2900

In re Application of: Michael F. Murray
Filed: 06/30/2000
Serial No.: 09/609,552
For: Treatment of Retrovirus Induced Derangements With Niacin Compounds
Atty. Docket No.: PHJM0609-002
Group Art Unit 1617
Examiner: Travers, Russell S.

7/8/03

PETITION AND FEE FOR EXTENSION OF TIME
UNDER 37 C.F.R. 1.136(A)

Dear Sir:

Applicant hereby petitions for a 3 month extension of time to respond to the Office Action mailed 12/18/2002.

A check for the extension fee (37 C.F.R. § 1.17(a)) is attached.

Respectfully submitted,

ELLIS & VENABLE PC

Joseph R. Meaney
Registration No. 45,276
Correspondence Address:
Ellis & Venable PC
101 North First Avenue, Suite 1875
Phoenix, Arizona 85003

06/23/2003 MDANTE1 00000069 09609552

01 FC:2253

465.00 DP



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/609,552
Filing Date	06/30/2000
First Named Inventor	Michael F. Murray
Art Unit	1617
Examiner Name	Travers, Russell S
Attorney Docket Number	PHJM0609-002

RECEIVED
JUN 24 2000
TECH CENTER 1600/2900

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	WERNER ER, FUCHS D, HAUSEN A, ET AL. Tryptophan Degradation in Patients Infected by Human Immunodeficiency Virus, Biol Chem Hoppe Seyler 1988; 369(5):337-40	
	✓	LARSSON M, HAGBERG L, NORKRANS G, FORSMAN A, Indole Amine Deficiency in Blood and Cerebrospinal Fluid From Patients With Human Immunodeficiency Virus Infection, J Neurosci Res, 1989; 23(4):441-6	
	✓	FUCHS D, MOLLER AA, REIBNEGGER G, STOCKLE E, WERNER ER, WACHTER H, Decreased serum Tryptophan in Patients With HIV-1 Infection Correlates With Increased Serum Neopterin and with Neurologic/psychiatric Symptoms, J Acquir Immune Defic Syndr, 1990;3(9): 873-6	
	j	FUCHS D, FORSMAN A, HAGBERG L, ET AL. Immune Activation and Decreased Tryptophan in Patients with HIV-1 Infection, J Interferon Res, 1990; 10(6): 599-603	
	?	FUCHS D, MOLLER AA, REIBNEGGER G, ET AL., Increased Endogenous Interferon-Gamma and Neopterin Correlate with Increased Degradation of Tryptophan in Human Immunodeficiency Virus Type 1 Infection, Immunol Lett, 1991; 28(3):207-11	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/609,552
Filing Date	06/30/2000
First Named Inventor	Michael F. Murray
Art Unit	1617
Examiner Name	Travers, Russell S
Attorney Docket Number	PHJM0609-002

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	✓	HEYES MP, BREW BJ, SAITO K, ET AL. Inter-relationships between Quinolinic Acid, Neuroactive Kynurenines, Neopterin and Beta 2-Microglobulin in Cerebrospinal Fluid and Serum of HIV-1-Infected Patients, J Neuroimmunol 1992; 40(1):71-80	
	✓	HORTIN GL, LANDTM, POWDERLY WG, Changes in Plasma Amino Acid Concentrations in Response to HIV-1 Infection, Clin Chem 1994; 40(5):785-9	
	✓	LAURICHESSE H, TAUVERSON I, GOURDON F, ET AL. Threonine and Methionine are Limiting Amino Acids for Protein Synthesis in Patients with AIDS, J Nutr 1998; 128(8): 1342-8	
	✓	HUENGESBERG M, WINER JB, GOMPELS M, ROUND R, ROSS J, SHAHMANESH M, Serum Kynurenine-to-tryptophan Ratio Increases with Progressive Disease in HIV-Infected Patients, Clin Chem 1998; 44(4): 858-62	
	✓	FU CASEY S, SWENDSEID M, JACOB ROBERT, MCKEE RALPH, Biochemical Markers for Assessment of Niacin Status in Young Men: Levels of Erythrocyte Niacin Coenzymes and Plasma Tryptophan, American Institute of Nutrition, 1989, 1949-1955	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.